Moderna Inc logo

MRNA - Moderna Inc Share Price

$161.38 11.5  7.7%

Last Trade - 14/05/21

Large Cap
Market Cap £45.97bn
Enterprise Value £40.61bn
Revenue £1.94bn
Position in Universe 192nd / 6846
Unlock MRNA Revenue
Relative Strength (%)
1m +2.26%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 108.4 205.8 135.1 60.2 803.4 18,311 15,417 +65.0%
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, ModernaInc revenues increased from $8.4M to $1.94B. Net incometotaled $1.22B vs. loss of $124.2M. Revenues reflect Grantrevenue increase from $3.9M to $194M, CollaborationArrangement increase from $3.2M to $10M. Basic Earnings perShare excluding Extraordinary Items increased from -$0.35to $3.05.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MRNA
Graphical History


MRNA Revenue Unlock MRNA Revenue

Net Income

MRNA Net Income Unlock MRNA Revenue

Normalised EPS

MRNA Normalised EPS Unlock MRNA Revenue

PE Ratio Range

MRNA PE Ratio Range Unlock MRNA Revenue

Dividend Yield Range

MRNA Dividend Yield Range Unlock MRNA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MRNA EPS Forecasts Unlock MRNA Revenue
Profile Summary

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
Incorporated July 22, 2016
Public Since December 7, 2018
No. of Shareholders: 74
No. of Employees: 1,300
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite , Nasdaq 100 ,
Exchange NASDAQ Global Select Market
Shares in Issue 401,527,789
Free Float (0.0%)
Eligible for
MRNA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MRNA
Upcoming Events for MRNA
Thursday 27th May, 2021
Moderna Inc Science Day
Tuesday 3rd August, 2021 Estimate
Q2 2021 Moderna Inc Earnings Release
Thursday 9th September, 2021
Moderna Inc R&D Day
Wednesday 27th October, 2021 Estimate
Q3 2021 Moderna Inc Earnings Release
Frequently Asked Questions for Moderna Inc
What is the Moderna Inc share price?

As of 14/05/21, shares in Moderna Inc are trading at $161.38, giving the company a market capitalisation of £45.97bn. This share price information is delayed by 15 minutes.

How has the Moderna Inc share price performed this year?

Shares in Moderna Inc are currently trading at $161.38 and the price has moved by 0.150k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Moderna Inc price has moved by 74.06% over the past year.

What are the analyst and broker recommendations for Moderna Inc?

Of the analysts with advisory recommendations for Moderna Inc, there are there are currently 2 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Moderna Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Moderna Inc next release its financial results?

Moderna Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Moderna Inc dividend yield?

Moderna Inc does not currently pay a dividend.

Does Moderna Inc pay a dividend?

Moderna Inc does not currently pay a dividend.

When does Moderna Inc next pay dividends?

Moderna Inc does not currently pay a dividend.

How do I buy Moderna Inc shares?

To buy shares in Moderna Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Moderna Inc?

Shares in Moderna Inc are currently trading at $161.38, giving the company a market capitalisation of £45.97bn.

Where are Moderna Inc shares listed? Where are Moderna Inc shares listed?

Here are the trading details for Moderna Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: MRNA
What kind of share is Moderna Inc?

Based on an overall assessment of its quality, value and momentum, Moderna Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Moderna Inc share price forecast 2021?

Shares in Moderna Inc are currently priced at $161.38. At that level they are trading at 11.07% discount to the analyst consensus target price of 0.00.

Analysts covering Moderna Inc currently have a consensus Earnings Per Share (EPS) forecast of 24.929 for the next financial year.

How can I tell whether the Moderna Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moderna Inc. Over the past six months, the relative strength of its shares against the market has been 59.22%. At the current price of $161.38, shares in Moderna Inc are trading at 38.88% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Moderna Inc PE Ratio?

The Moderna Inc PE ratio based on its reported earnings over the past 12 months is 0.129k. The shares are currently trading at $161.38.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Moderna Inc?

Moderna Inc's management team is headed by:

Stephane Bancel - CEO
Juan Andres - CTO
Marcello Damiani - OTH
Lori Henderson - GCN
Stephen Hoge - PRE
Noubar Afeyan - NEC
Stephen Berenson - IND
Robert Langer - IND
Elizabeth Nabel - IND
Francois Nader - IND
Tracey Franklin - CHO
David Meline - CFO
Ray Jordan - OTH
Sandra Horning - IND
Corinne Le Goff - OTH
Who are the major shareholders of Moderna Inc?

Here are the top five shareholders of Moderna Inc based on the size of their shareholding:

Baillie Gifford & Co. Investment Advisor
Percentage owned: 11.29% (45.3m shares)
Flagship Ventures Venture Capital
Percentage owned: 6.06% (24.3m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 4.71% (18.9m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.07% (16.3m shares)
Langer (Robert S Jr) Individual Investor
Percentage owned: 2.87% (11.5m shares)
Similar to MRNA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.